Volume 5 Supplement 3

3rd World Congress of the Global Arthritis Research Network (GARN): International Arthritis Summit

Open Access

Galectin-3 and galectin-3 binding protein in rheumatoid arthritis

  • S Ohshima1, 2,
  • S Kuchen2,
  • C Seemayer2,
  • FT Liu3,
  • M Neidhart2,
  • RE Gay2 and
  • S Gay2
Arthritis Res Ther20035(Suppl 3):137

https://doi.org/10.1186/ar938

Published: 12 September 2003

Galectin-3 (Gal-3) is one of the soluble lectins that has key functions in inflammation, chemotaxis, cell adhesion and apoptosis. We examined the role of Gal-3 and Gal-3 binding protein (Gal-3BP) in rheumatoid arthritis (RA). Localization of Gal-3 and Gal-3BP in rheumatoid synovium was examined by immunohistochemistry and in situ hybridisation. Gal-3 and Gal-3BP concentrations in plasma and synovial fluid were measured by ELISA. Gal-3 protein and mRNA stained throughout the synovial membrane, and Gal-3BP expressed at the site of erosion in RA. Lower and scattered expression of both Gal-3 and Gal-3BP were detected in osteoarthritis synovium and normal synovium. ELISA revealed a marked increase of Gal-3 and Gal-3BP in synovial fluid of patients with RA compared with osteoarthritis patients and normal controls. Furthermore, the level of Gal-3 in serum correlated with the level of C-reactive protein in RA. In vitro, Gal-3 can induce the production of matrix metalloproteinase (MMP)-1, MMP-3, and MMP-9 in synovial fibroblasts in a dose-dependent manner. Our data indicate that Gal-3 and Gal-3BP represent novel markers of disease activity in RA. Moreover, Gal-3 might contribute to the destruction of bone/cartilage in RA by the induction of MMPs.

Authors’ Affiliations

(1)
Department of Molecular Medicine, Osaka University Graduate School of Medicine
(2)
Center of Experimental Rheumatology, University Hospital
(3)
Department of Dermatology, University of California, Davis, School of Medicine

Copyright

© BioMed Central Ltd 2003

Advertisement